Martin Hubbes, CFA AnorMed Inc AOM-T DON'T BUY Mar 06, 2002

When their cancer drug didn't meet expectations, their partner dropped out. Have a lot of cash, but there are better companies available.

Martin Hubbes, CFA

Unknown

Unlock Rating

$4.450

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

TOP PICK

Has partnerships with leading global pharmaceuticals. Products are now in WAIT stage.

TOP PICK

In phase 2 for aids, cancer drugs & phase 3 for a kidney failure drug. Big partners

BUY

One of the best 2/3 junior biotechs. Working on 3 products. Good partnerships.

TOP PICK

Likes their product AMD-3100 which harvests bone marrow cells with remarkable effect prior to chemo therapy. Lots of cash. Has more upside and less risk than the average biotech.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Martin Hubbes, CFA AnorMed Inc AOM-T DON'T BUY Mar 06, 2002

You might be interested:

AnorMed Inc(AOM-T)

AnorMed Inc(AOM-T)

AnorMed Inc(AOM-T)

AnorMed Inc(AOM-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights